Compare HLP & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLP | FHTX |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.2M | 173.4M |
| IPO Year | 2021 | 2020 |
| Metric | HLP | FHTX |
|---|---|---|
| Price | $2.80 | $1.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.17 |
| AVG Volume (30 Days) | 87.6K | ★ 1.1M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.98 |
| P/E Ratio | $51.63 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $0.34 | $1.79 |
| 52 Week High | $2.85 | $7.61 |
| Indicator | HLP | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 83.55 | 15.02 |
| Support Level | $0.78 | $1.79 |
| Resistance Level | N/A | $5.35 |
| Average True Range (ATR) | 0.16 | 0.25 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 98.52 | 2.07 |
Hongli Group Inc is an offshore holding company. Through its subsidiaries, it is engaged in the cold-rolled steel profile manufacturing in China. Its main business operation focuses on the design, production, deep processing, and sales of custom-made profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation industries. The group operates in a single segment, which manufactures and sells agricultural machinery cab assemblies, construction machinery cab assemblies, excavator cab assemblies, and special-shaped steel pipes. It generates the majority of its reveneue from PRC.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.